title: Receptor for advanced glycation end products (RAGE) gene polymorphism and cardiovascular disease in end-stage renal disease patients.
abstract: OBJECTIVE
  Receptor for advanced glycation end products (RAGE) contributes to the pathogenesis of vascular and inflammatory diseases. We investigated whether the functional polymorphism in the promoter region of the RAGE gene (-374 T/A) influences development of cardiovascular disease in the end-stage renal disease (ESRD) patients.
  
  
  METHODS
  The cohorts of 1866 ESRD patients and 1143 healthy subjects were genotyped by polymerase chain reaction (PCR) for the RAGE variant rs1800624.
  
  
  RESULTS
  The genotype and allele frequencies did not differ significantly between ESRD patients and controls. There was no significant difference in the genotype distribution when patients with CVD were compared to those without it (p for A allele = 0.62). After stratifying CVD patients according to CVD clinical phenotype, the ESRD patients with stroke had a lower frequency of A allele than patients without CVD (0.12 vs. 0.21, p = 0.027). To confirm this finding, we genotyped 163 patients with ischemic stroke but without renal disease. In this group, the AA/TA genotypes were also significantly associated with lower risk of stroke (OR 0.46, p = 0.0002).
  
  
  CONCLUSIONS
  Our data suggest that the presence of the A allele of -374 T/A polymorphism in the RAGE gene has a protective effect against stroke.
authors.affiliation: Laboratory for DNA Analysis and Molecular Diagnostics, Department of Nephrology, Medical University of Lublin, Lublin, Poland. Electronic address: monika.buraczynska@umlub.pl.
authors.forename: Monika
authors.initials: M
authors.lastname: Buraczynska
authors.affiliation: Laboratory for DNA Analysis and Molecular Diagnostics, Department of Nephrology, Medical University of Lublin, Lublin, Poland.
authors.forename: Wojciech
authors.initials: W
authors.lastname: Zaluska
authors.affiliation: Department of Neurology, Medical University of Lublin, Lublin, Poland.
authors.forename: Kinga
authors.initials: K
authors.lastname: Buraczynska
authors.affiliation: Laboratory for DNA Analysis and Molecular Diagnostics, Department of Nephrology, Medical University of Lublin, Lublin, Poland.
authors.forename: Dorota
authors.initials: D
authors.lastname: Markowska-Gosik
authors.affiliation: Laboratory for DNA Analysis and Molecular Diagnostics, Department of Nephrology, Medical University of Lublin, Lublin, Poland.
authors.forename: Andrzej
authors.initials: A
authors.lastname: Ksiazek
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D016022:Case-Control Studies; D005260:Female; D005787:Gene Frequency; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D000067759:Receptor for Advanced Glycation End Products / Q000235:genetics*
chemical_list: D000067759:Receptor for Advanced Glycation End Products
keywords: Cardiovascular disease; End-stage renal disease; Gene polymorphism; Genetic susceptibility; RAGE gene